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Summary 
Although the immunologic  basis of protective immunity in human immunodeficiency  virus type 
1 (HIV-1) infection has not yet been defined, virus-specific cytotoxic T lymphocytes (CTL) are 
likely to be an important host defense and may be a critical feature of an effective vaccine. These 
observations, along with the indusion of the HIV-1 envelope in the majority of vaccine candidates 
presently in clinical trials, underscore the importance of the precise characterization  of the cellular 
immune responses to this protein. Although humoral immune responses to the envelope protein 
have been extensively characterized, relatively little information is available regarding the envelope 
epitopes recognized by virus-specific  CTL and the effects of sequence variation within these epitopes. 
Here we report the identification of two overlapping CTL epitopes in a highly conserved region 
of the HIV-1 transmembrane envelope protein, gp41, using CTL clones derived from two seropositive 
subjects. An eight-amino acid peptide was defined as the minimum epitope recognized by HLA- 
B8-restricted CTL derived from one subject, and in a second subject, an overhpping nine-amino 
acid peptide was identified as the minimal epitope for HLA-B14-restricted  CTL dones. Selected 
single amino acid substitutions representing those found in naturally occurring HIV-1 isolates 
resulted in partial to complete loss of recognition of these epitopes. These data indicate the presence 
of a highly conserved region in the HIV-1 envelope glycoprotein that is immunogenic for CTL 
responses.  In addition, they suggest that natural sequence variation may lead to escape from 
immune detection by HIV-l-specific  CTL. Since the region containing these epitopes has been 
previously shown to contain an immunodominant B cell epitope and also overlaps with a major 
histocompatibility complex dass II T cell epitope recognized by CD4 + CTL from HIV-1 rgp160 
vaccine recipients,  it may be particularly important for HIV-1 vaccine development. Finally, the 
identification of minimal CTL epitopes presented by class I HLA molecules should facilitate 
the definition of allde-specific  motifs. 
T 
he extensive sequence diversity exhibited by HIV-1, es- 
pecially in the envelope glycoprotein, represents a con- 
siderable challenge to the development of a vaccine against 
this retrovirus and may contribute to the ultimate failure of 
the immune system in HIV-1 seropositive subjects to contain 
viral replication. Detailed study of the recognition of HIV-1 
epitopes by the human immune system may therefore facili- 
tate the development of an HIV-1 vaccine and advance our 
understanding of the pathogenesis of AIDS. Although a con- 
siderable amount is known about humoral immune responses 
This work was presented in part at the Seventh International  Conference 
on AIDS, Florence, Italy, 1991, abstract W. A.  1206. 
to the HIV-1 envelope, our knowledge of specific epitopes 
recognized by cellular immune responses, and in particular 
epitopes recognized by CTL, remains incomplete. CTL are 
an important component of the host immune response against 
many viral infections, and the observations that CTL inhibit 
HIV-1 replication in vitro (1) and a decline in HIV-l-specific 
CTL activity may be associated with clinical progression to 
AIDS (2) suggest that HIV-l-specific  CTL may play an im- 
portant role in the inhibition of viral replication in vivo. These 
considerations have prompted us to perform a detailed ex- 
amination of the CTL response to the HIV-1 envelope in in- 
fected persons. 
Identification of CTL epitopes in the HIV-1 envelope gly- 
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restricted and non-HLA-restricted envelope-specific cytolytic 
cells in PBMC (3-7). The evaluation of  envelope-specific CTL 
responses using CTL dones should circumvent this problem 
and allow precise characterization of epitopes recognized by 
HLA-restricted CTL (8,  9).  In the present study, we have 
identified CTL epitopes in the HIV-1 envelope glycoprotein 
using CD8 + CTL clones derived from two HIV-1 seroposi- 
tire subjects. CTL epitopes restricted by two different HLA 
class I  alleles were mapped to a  10-amino acid  (aa)  1 con- 
served region of gp41.  Further fine mapping demonstrated 
that this area contained an eight-aa HLA-B8-restricted CTL 
epitope and an overlapping  nine-aa HLA-B14-restricted  CTL 
epitope.  Analysis  of the effects  of aa  substitutions corre- 
sponding to natural sequence  variation was performed for 
both CTL epitopes and demonstrated that a single aa change 
could lead to a loss of CTL recognition. These results sup- 
port the hypothesis that sequence  variation in HIV-1  may 
contribute to the evolution of virus variants that are no longer 
recognized by the host immune response. 
Materials and Methods 
Subjects.  Two HIV-1 seropositive  subjects who were known to 
have significant envelope-specific  CTL activity were selected for 
study (8, 9). Both subjects gave written informed consent and the 
study was approved  by the Massachusetts  General  Hospital Human 
Studies Committee. During this study, both subjects were asymp- 
tomatic; CD4 + lymphocytes were 145/mm  3 in subject 010-035i 
and 900/ram 3 in subject 010-115i. Subject 010-035i was referred 
to as subject subject 63 in a previous report from this laboratory (8). 
Cell Lines.  EBV-transformed  B lymphobhstoid cell lines (B- 
LCL) were established and maintained as described previously (4) 
in RPMI 1640 (Sigma Chemical Co., St. Louis, MO) containing 
20% (vol/vol) heat-inactivated  FCS (Sigma  Chemical Co.). RPMI 
1640 used for all cell lines was supplemented with t-glutamine (2 
raM), penicillin (50 U/m1), streptomycin (50/~g/ml), and Hepes 
(10 raM). Ailogeneic B-LCL were also obtained from the Amer- 
ican Society  for Histocompatibility and Immunogenetics B cell line 
repository. All B-LCL were free of mycoplasma  infection by stan- 
dard culture techniques. 
HLA Typing.  FILA  typing was performed  by the Massachusetts 
General Hospital Tissue Typing Laboratory using standard sero- 
logical techniques. 
Recombinant  Vaccinia Viruses.  Preparation of recombinant vac- 
cinia viruses expressing serial truncations of the HIV-1 envelope 
glycoprotein has been previously described (10). In brief, a series 
of truncated envelope genes were prepared from the BH8 isolate 
of HIV-1 (11) by digestion at unique restriction enzyme sites, and 
recombinant vaccinia  viruses generated using homologous recom- 
bination..The recombinant vaccinia  virus vAbt141 expressing the 
full-length p55 gag protein (12) was kindly provided by Drs. Gail 
Mazzara and Dennis Panicali (Therion Biologics  Inc., Cambridge, 
MA). Recombinant vaccinia  viruses expressing the HIV-1 reverse 
transcriptase (RT) (VCF21) (13) and the control/acZ (VSC8) genes 
were also used in these studies. 
t Abbreviations used in this paper: aa, amino  acid; B-LCL,  B lymphoblastoid 
cell line; RT, reverse transcriptase. 
STnthetic HIV-1  Peptides.  Synthetic peptides corresponding to 
the HIV-1 envelope  PV22 sequence (14) were synthesized  by Mul- 
tiple Peptide Systems (San Diego, CA) using t-butoxycarbonyl 
NH2-protected aa and 4-methylbenzhydramine  resin (15). Peptides 
were cleaved from the resin with anhydrous hydrogen fluoride, 
washed with ether, extracted with 10% acetic acid, and evaluated 
for purity by reverse-phase analytical HPLC. Peptides consisted of 
a series of peptides 25 aa in length and overlapping by eight aa, 
and were synthesized  as COOH-terminal amides, unless otherwise 
noted. AU aa are numbered as indicated for the HXB2R sequence 
(16) and references  to other peptides and epitopes  have  been modified 
accordingly. Peptide gp41/576 (numbering of NH2-terminal aa 
changed to be consistent with Myers et al. [16]) was obtained from 
American BioTechnologies  (Cambridge, MA). Peptide CP3 was 
provided by Repligen Corp. (Cambridge, MA), and peptide DP31 
was donated by Drs. Kent Weinhold and Stefano Butto (Duke 
University, Durham, NC). Additional smaller peptides (8-15 aa) 
were synthesized  for fine mapping using a technique similar to that 
described above (17). Lyophilized peptides were reconstituted at 
2  mg/ml in  sterile distilled water  with  10%  DMSO  (Sigma 
Chemical  Co.) with or without 1 mM dithiothreitol (Sigma Chem- 
ical Co.). 
Isolation of  HIF:-I Envelope-specific CTL Clones.  CTL clones  were 
isolated and maintained  as described  previously  (8, 9). Briefly,  PBMC 
obtained from seropositive  subjects  by separation  on FicoU-Hypaque 
(Sigma Chemical Co.) were incubated at 50 or 25 cells per well 
in 96-well plates with 200/~1 of feeder cell solution containing 
106/ml irradiated allogeneic  PBMC from HIV-1 seronegative sub- 
jects in RPMI 1640 with 10% heat-inactivated FCS (R10) sup- 
plemented with 100 U/ml of human rlL-2 (Hoffman-La Roche, 
Nutley, NJ; DuPont Co., Wilmington, DE; or Boehringer Mann- 
heim Biochemicals,  Indianapolis,  IN). The CD3-specifc mAb 12F6 
(18) was added at 0.1/~g/ml as a stimulus to T cell proliferation. 
After 2-3 wk, cells from wells demonstrating growth were then 
transferred to 24-well plates and restimulated by adding 1 ml of 
rlL-2-containing  medium  with  irradiated allogeneic  PBMC 
(106/ml) and anti-CD3 mAb (0.1/~g/ml).  Approximately 2 wk 
later, clones were screened for CTL activity against autologous 
targets expressing the HIV-1 envelope glycoprotein or IacZ con- 
trol. Clones exhibiting envelope-specific  CTL activity were then 
restimulated every 10-14 d with anti-CD3 mAb and irradiated al- 
logeneic PBMC. 
Production of  an Envelop-specific CTL Lin~  An envelope  peptide- 
specifc CTL line was derived using in vitro stimulation of PBMC 
obtained  from  subject 010-035i with an  autologous,  peptide- 
sensitized CD4 + T lymphocyte  clone. CD4 + T lymphocyte  clones 
were prepared by plating PBMC from subject 010-035i at limiting 
dilution in the presence of the bispecific mAb CD3,8 (18), irradi- 
ated allogeneic  PBMC from HIV-1 seronegative  donors, and R10 
with rib2 (100 U/ml). The bispecific mAb CD3,8 leads to the 
selective expansion of CD4 § T lymphocytes  by the lysis of CD8 § 
lymphocytes via redirected cytotoxicity and the concurrent activa- 
tion of CD3+CD4 + lymphocytes (18). Wells exhibiting growth 
after 2 wk were restimulated  using irradiated  PBMC from seronega- 
tive donors and the CD3-specific mAb 12F6 as described below. 
Cell lines obtained using this technique were screened for CD4* 
expression by flow cytometry, and cell lines with >98% CD4 ex- 
pression were maintained with restimulation as described for CTL 
clones every 2-3 wk. These cells were then sensitized with a syn- 
thetic peptide (env/128) containing a CTL epitope by incubating 
them with 100/~g/ml  ofpeptide for 2 h, washing twice with RPMI 
1640, and then irradiating with 3,000 rad. Primary stimulation 
was carried out with peptide-sensitized  CD4 + lymphocytes  mixed 
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concentration of PBMC in R10 of 4-6  x  10./ml. After 4-7 d, 
rlL-2 was added to produce a final concentration of 10 U/ml. The 
peptide-specific CTL line was maintained by restimulation every 
7-14 d with irradiated HIV-1 seronegative allogeneic PBMC and 
autologous peptide-sensitized, irradiated CD4 § lymphocytes in 
R10 supplemented with 10 U/ml rlL-2. 
Flow Cytometry  Analysis.  Cells  to be analyzed were incubated 
with a fluorescent probe-conjugated anti-CD4 mAb, anti-CD8 
mAb, or a similarly  labeled control mAb (Coulter Electronics, Hi- 
aleah, FL) and analyzed with a FACScan  |  flow cytometer (Becton 
Dickinson & Co., Mountain View, CA) as previously  described (9). 
CytotoxicityAssay.  Target  ceils  consisted  of  B-LCL  infected  with 
recombinant vaccinia or preincubated with synthetic HIV-1 pep- 
tides. Vaccinia-infected  targets were prepared by incubating 2.5-10 
x  106 B-LCL  in log-phase growth with recombinant vaccinia at 
1-2 PFU/cell  for 16 h at 37~  CeiLs  were then labeled  with 100-150 
/~Ci of Naz(SlCrO4) (New England Nuclear, Boston, MA) for 
45-60 min and washed three times with R10. Peptide-coated  targets 
were obtained by incubating 2-3  x  106 B-LCL with peptide for 
60 min during SlCr labeling. Cytolytic activity was determined 
in a standard SlCr-release assay (4) using U-bottomed microtiter 
plates containing 104 targets per well. Plates were incubated in a 
humidified incubator at 37~  either for 4 h (CTL clones) or 5 h 
(peptide-specific CTL line). All assays were performed in dupli- 
cate. Supernatants were then harvested and counted on a Cobra 
Gamma Counter (Packard Instrument Co., Inc,, Downers Grove, 
IL), and percent lysis  was determined from the formula: 100x [(ex- 
perimental release -  spontaneous release)/(maximum release - 
spontaneous release)]. Maximum release was determined by lysis 
of targets in water or detergent (1% Triton X-100; Sigma Chem- 
ical Co.). Spontaneous release was <30% of maximal release for 
aU reported assays. 
Results 
Isolation of  Envelope-specific  CTL Clones.  PBMC from two 
HIV-1 seropositive  subjects were plated at limiting dilution 
in the presence of a CD3-specific mAb, irradiated PBMC from 
seronegative subjects, and rIL-2. Envelope-specific CTL were 
Table  1.  Cytolytic  Activity of HIV-I Envelope-specific 
CTL Clones 
Percent specific lysis* 
Subject  Clone  lac  gag  RT  Env 
010-035i  35D45  2  2  0  72 
010-115i  115Gll  0  2  0  58 
115H10  1  0  0  73 
115J7  0  3  0  71 
115N10  0  0  0  72 
*  Target cells were prepared from autologous  EBV-transformed  B lym- 
phoblastoid cell lines infected  with recombinant vaccinia  virus express- 
ing the control/acZ  gene (lac), HIV-1 p55 gag (gag), reverse  transcriptase 
(RT), or envdope (Env) proteins. The E/T ratio  was 10:1 for all clones. 
typically  identified in 0.25-0.75% of all wells and comprised 
'~30-50% of all HIV-l-spedfic CTL. Five envelope-specific 
CTL dones, which were stable in long-term culture and could 
be fully characterized, are described in this paper.  All were 
highly specific  for the HIV-1 envelope (Table 1) and were found 
to be CD4-CD8 + by flow cytometry (data not shown). 
Envelope-specific CTL Clones Are HLA  Class I Restricted. 
The HLA restriction of envelope-specific lysis was defined 
for each CTL clone using a panel of allogeneic target cells 
matched at one or more class I alleles. Consistent with their 
CD8 + phenotype, all CTL dones were found to be HLA 
class I restricted. Clone 35D45  from subject  010-035i  was 
restricted by the HLA-B8 molecule (Fig.  1).  Testing of all 
four clones from subject 010-115i against allogeneic targets 
infected with recombinant vaccinia virus demonstrated lysis 
of targets matched at HLA-B14, either in the presence or ab- 
sence of the Cw8 allele (Table 2). To further exclude restric- 
tion by the Cw8 allele, which is in dysequilibrium linkage 
with B14 (19), done 115H10 was also tested against other 
allogeneic B-LCL and found to lyse additional target cells 
that express B14 but not Cw8 (data not shown). 
Mapping of Epitope Specificity Using Recombinant Vaccinia 
Expressing Truncated  HIV1 Envelope  Proteins.  Initial mapping 
of the epitope specificity of envelope-specific CTL tones was 
performed using a panel of autologous target cells infected 
with recombinant vaccinia vectors expressing  serial trunca- 
tions of the HIV-1 envelope. Clone 35D45 and tones 115H10, 
115J7, and 115N10 lysed target cells expressing envelope con- 
structs containing the NH2-terminal 635  aa of the HIV-1 
envelope (vPE16, vPE17, and vPE18), but did not recognize 
targets expressing the 393 aa or shorter truncations (vPE20, 
vPE21, vPE22) (Fig. 2), identifying the region of aa 393-635 
as containing the epitopes recognized by these clones. Clone 
115Gll was not tested against targets expressing  truncated 
Autologous 
A1 
A1, B8 
A1, All, Cw4 
B8 
Bw62 
% Envelope-Specific Lysis 
Figure  1.  The CTL clone 35D45 is restricted  by the HLA-B8 mole- 
cule. Target cells consisted of autologous or allogeneic  B-LCL  matched 
at the indicated  HLA alleles, which  were  inf~ed with recombinant  vac- 
cinia virus expressing either the HIV-1 envelope  glycoprotein  or the/acZ 
control. Targets  were  incubated  with effector  cells at an E/T ratio  of  2.5:1. 
Envelope-specific  lysis  was calculated  for each target tested  by subtracting 
the specific  lysis of targets infected  with the control vacdnia  virus from 
the specific lysis of envelope-expressing  targets. Lysis  of control targets 
was <12% for all assays. 
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Are HLA  Class I Restricted 
Envelope-specific iysis" 
Shared HLA alleles 
of target cellt  115Gll  115H10  115J7  115N10 
Autologous  28  53  50  53 
A2  2  1  0  0 
A28  0  0  0  0 
B14, Cw8  13  16  18  17 
BI4  21  53  51  ND 
Bw52  0  0  0  0 
" All CTL clones were incubated with target  cells at an E/T ratio of 
10:1. Envelope-specif~ 1)~ was calculated for each target tested by sub- 
tracting the specific lysis of lac-expressing targets from the specific lysis 
of envdope-expr~ssing  targets.  Lysis of lac-expressing target  cells was 
<2% for all targets. 
* Targets consisted of autologous or allngeneic B-LCL matched at indi- 
cated HLA antigens infected with recombinant vaccinia virus expressing 
either  the HIV-1  envelope or/acZ control. 
envelope proteins, but the specificity of this clone was subse- 
quently  defined  using  peptide-sensitized  target  cells (see 
below). 
x .f oeo.   cogm   by   z0pe-spe  c 
CTL Clones.  Epitope specificity was then defined for each 
CTL clone using autologous target cells incubated  with a 
series of overlapping peptides, 25 aa in length with an eight 
aa overlap, which spanned aa 393-635. Remarkably, the HLA- 
B8-restricted CTL clone 35D45 from subject 010-035i and 
all of the HLA-B14-restricted CTL clones from subject 010- 
115i recognized the same envelope peptide env/128, aa 575- 
599, sequence  QLQARILAVERYL~LLGIWGC~ (single 
letter code) with no recognition of any other synthetic pep- 
tide spanning this  sequence (Table 3). 
Generation of  an Envelope-specific CTL Line from Subject 010- 
035i.  Although preliminary fine mapping of the epitope 
specificity of CTL clone 35D45 was performed (see below), 
the limited ability to propagate clone 35D45 precluded defini- 
tive fine mapping of the epitope specificity of this clone. At- 
tempts to produce a CTL line specific for peptide env/128 
from subject 010-035i by in vitro stimulation of PBMC with 
synthetic peptide as previously described for influenza (20) 
were unsuccessful (data not shown). To fine map the HLA- 
B8-restricted CTL epitope, an envelope-specific  CTL line was 
therefore derived from subject 010-035i using an autologous, 
envelope  peptide-sensitized  CD4 +  T  lymphocyte clone. 
After primary and secondary stimulations  of PBMC with 
an  irradiated  CD4 + T  lymphocyte clone sensitized  with 
peptide env/128,  a CTL line was derived that was highly 
specific for the sensitizing peptide (Fig. 3). This CTL line 
also recognized autologous target cells infected with recom- 
binant vaccinia virus expressing the HIV-1 envelope (data not 
shown). CTL lines generated using this technique maintained 
highly specific cytolytic activity  for  peptide env/128  for 
8-12 wk  when restimulated  every  7-10  d  with peptide- 
sensitized autologous CD4 ÷ lymphocytes and irradiated al- 
logeneic PBMC.  Experiments using peptide-sensitized  al- 
logeneic target cells confirmed that lysis by the 35/env/128 
CTL line was restricted by the HLA-B8 allele, as was ob- 
served for clone 35D45  (data not shown). 
HLA-B8- and B14-restricted CTL Recognize Overlapping Epi- 
topes in gp41.  Fine mapping of the specific epitopes recog- 
nized by gp41-specific CTL was performed by analyzing the 
lysis of target cells sensitized with peptides  containing se- 
quences within peptide env/128 (aa 575-599).  Initial epitope 
mapping revealed that both HLA-B8-restricted  CTL (clone 
35D45  and line 35/env128)  and HLA-B14-restricted  CTL 
(clones 115H10 and 115J7) recognized peptides that contained 
the common sequence ERYLKDQQLLG (an 584-594) (Table 
4). However, peptides gp41/576  and GGO6-15, which con- 
tained only the NH2-terminal nine aa (ERYLKDQQL) of 
this  shared  sequence,  were recognized  by  the  HLA-B14- 
restricted CTL but not by the HLA-B8-restricted CTL, sug- 
gesting that two different overlapping CTL epitopes existed 
within this  region. 
To define precisely both the HLA-B8- and B14-restricted 
gp41 CTL epitopes, peptides with sequential single aa deletions 
were used to sensitize autologous target cells for lysis by CTL 
derived from both subjects. Deletions of a single aa at either 
end or the nine-aa sequence ERYLKDQQL (an 584-592) 
resulted in loss of recognition by the HLA-B14-restricted  clones 
115H10 and 115J7 (Table 4), identifying this sequence as the 
minimum epitope required for recognition by these clones. 
Testing of the remaining gp41-speeific clones obtained from 
subjects 010-115i, 115Gll, and 115N10 against the same panel 
of peptides produced an identical pattern of epitope specificity 
% Envelope-Specific  Cytotoxicity 
pe16  '~  ~  _851~  53  21  22  24 
pe17  ".  74"Z'aa  72  73  78  75 
pe18  ~  75  78  78  79 
pc20  ~  4  0  2  0 
pe21  ~  1  0  0  0 
pc22  ~  2  0  1  0 
Figure 2.  Epitope mapping of envelope-specific  CTL 
clones using recombinant vaccinia  viruses expressing serial 
truncations of the HIV-1 envelope. Autologous  B-LCL 
were infected with recombinant  vaccinia expressing serial 
truncations of the HIV-1 envelope or the/acZ control. 
The length of HIV-1 envelope  expressed by each construct 
is indicated. Clones were incubated with target cells at 
several E/T ratios, and representative data are shown for 
clone 35D45 at an E/T ratio of 5:1 and clones 115HI0, 
115J7, and 115N10  at an E/T ratio of 10:1. Envelope-specific 
lysis was caicuhted  for each target  by subtracting  the 
specific lysis of targets infected with the control vaccinia 
virus from the specific  lysis of envelope-expressing  targets. 
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Percent  specific lysis* 
Peptide  Amino acids  35D45  115H10  115J7  115N10 
env/117  388-412  2  0  0  1 
env/118  405--429  2  1  1  0 
env/119  422-446  0  0  1  1 
env/120  439-463  1  0  1  0 
env/121  456-480  2  0  1  1 
env/122  473-497  1  1  0  1 
env/123  490-514  2  0  1  0 
env/124  507-531  2  0  0  0 
env/125  524-548  1  0  1  1 
env/126  541-565  1  0  0  0 
env/127  558-582  1  0  0  0 
env/128  575-599  66  38  22  39 
env/129  592-616  0  0  0  1 
env/130  609-633  1  0  0  0 
" CTL clones were incubated with autologous target cells at an E/T ratio of 4:1 (35D45)  or 10:1 (115H10,  115J7, 115N10).  Peptide-sensitized 
target cells were prepared by incubating autologous B-LCL with 100/zg/ml of the indicated peptide for 60 rain during sICr labeling. The sequence 
of peptide env/128  is QLQARILAVERYLKDQQLLGIWGCS. 
100. 
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Generation of an HIV-I envelope peptide--st~tic CTL line.  Figure  3. 
PBMC from an HIV-1 seropositive subject (subject 010-035i) were used 
as effector cells either fresh (A) or after a single (B) or second (C) stimula- 
tion with a peptide env/128--sensitized irradiated autologous CD4 + lym- 
phocyte clone and irradiated allogeneic PBMC. Targets consisted of autol- 
ogous B-LCL incubated either with the peptide env/128 or culture medium 
alone (control). 
(data not shown). In a similar fashion, deletions of single 
aa identified the eight-aa sequence YLKDQQLL (aa 586-593) 
as the putative minimum epitope for the HLA-B8-restricted 
CTL line 35/env/128 (Table 4). The octamer corresponding 
to the HLA-B8-restricted gp41 minimum epitope, synthe- 
sized as a COOH-terminal acid, was able to sensitize target 
cells for lysis by the 35/env/128 CTL line at concentrations 
as low as 100 pmol (data  not shown). 
Effects of Sequence Variation on Recognition by HLA-B8- and 
B14-restricted CTL.  Given the relatively high degree of vari- 
ability in the HIV-1 envelope glycoprotein, we wished to assess 
the effects of sequence variation exhibited by diverse HIV-1 
isolates on recognition by envelopespedfic CTL. Peptides 
were synthesized that contained both the HLA-B8- and B14- 
restricted gp41 CTL epitopes and exhibited aa substitutions 
corresponding to sequenced HIV-1 isolates and the HIV-2 
ROD isolate.  The introduction of a conservative  substitu- 
tion (Arg for Lys) at position 588 had no significant  effect 
on recognition of the variant peptide by B14-restricted CTL, 
but resulted in a partial loss of lysis by Bg-restricted CTL 
(Fig. 4). However,  the nonconservative substitution of Gin 
for Lys at this same position abolished recognition by both 
HLA B8- and B14-restricted CTL. Interestingly, the introduc- 
tion of a second aa substitution, Arg for Gin substitution 
at position 591, resulted in recognition by both HLA-B8- 
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Percent specific lysis" 
Peptide  Sequence  35D45  35/env128  115H10  115J7 
env/128  QLQARILAVERYLKDQQLLGIWGCS  74  37  38  31 
gp41/576  LQARILAVERYLKDQQL  7  5  77  64 
GGO6-15  LQARILAVERYLKDQQL (GC)  10  10  62  67 
GGO6-16  AVERYLKDQQLLGIWGC  90  40  44  50 
CP3  ILAVERYLKDQQLLG  (C)  81  66  34  22 
DP31  ERYLKDQQLLGIWGCSGKLICG  74  32  83  59 
env/128A  AVERYLKDQQLLGIW  ND  34  48  43 
env/128B  AVERYLKDQQLLGI  ND  43  46  46 
env/128C  AVERYLKDQQLLG  N D  39  58  26 
env/128D  AVERYLKDQQLL  ND  35  57  40 
env/128E  AVERYLKDQQL  ND  6  71  77 
env/128F  AVERYLKDQQ  ND  0  7  3 
env/128H  AVERYLKD  ND  1  7  6 
env/128I  VERYLKDQQLLGIW  ND  22  70  62 
env/128J  ERYLKDQQLLGIW  ND  34  83  83 
env/128K  RYLKDQQLLGIW  ND  35  2  7 
env/128L  YLKDQQLLGIW  ND  39  0  4 
env/128M  VEIkYLKDQQLL  ND  39  50  50 
env/128 N  VERYLKDQQL  ND  4  83  81 
env/1280  ERYLKDQQL  ND  8  87  80 
env/128P  VERYLKDQQ  ND  0  3  1 
" Effector  cells  consisted  of the HLA-B8-restricted  CTL clone  35D45 and CTL line 35/env128 derived  from subject 010-035i or the HLA-B14-restricted 
CTL clones 115H10 and 115J7 derived from subject 010-115i. Each effector  cell was tested at multiple E/T ratios. Representative  data are shown 
for the CTL clone 35D45 at an E/T of 2:1, the CTL line 35/env128 at an E/T ratio of 5:1, and for the CTL clones 115H10 and 115J7 at an 
E/T ratio of 3:1. Targets consisted of autologous B-LCL incubated with the indicated peptide for 60 min at a final concentration of 100/~g/ml 
during slCr labeling. Amino acids enclosed in parentheses indicate peptide amino acids that do not correspond to the H1V-1 sequence. 
and B14-restricted CTL, although sensitization required higher 
concentrations than the corresponding HXB8 peptide. The 
observation that a second aa substitution can restore recog- 
nition of a variant peptide has also been made for a murine 
cytomegalovirus epitope (21). The peptide corresponding to 
the HIV-2 ROD sequence was not able to sensitize  autolo- 
gous target cells for lysis by CTL derived from either subject. 
Discussion 
These data identify a highly conserved region of the gp41 
transmembrane protein as a target for class I-restricted CTL 
and define within this region two distinct, overlapping T 
cell epitopes.  Based on their recognition of synthetic pep- 
tides corresponding to natural sequence variation, CTL specific 
for these epitopes are able to recognize >90% of sequenced 
North American isolates (16). Structural requirements for the 
conservation of this region of HIV-1 may be related to func- 
tions of the gp41 protein or selection at the lewd of nucleic 
acid, as the region encoding these CTL epitopes corresponds 
to  the end of the rew-responsive element (22,  23).  These 
findings of a cdl-mediated response  directed at conserved 
regions of the HIV-1 envelope are consistent with those of 
Earl et al.  (10), who isolated CD8 § CTL that recognized 
divergent HIV-1 strains, although specific epitopes were not 
identified, and with those of other investigators who have 
documented T helper cell responses against conserved regions 
of the HIV-1 envelope  (24).  Type-specific CTL directed at 
highly variable regions of the HIV-1 envelope  glycoprotein 
have also been identified (25, 26, and R. P. Johnson, C. Jassoy, 
and B. D. Walker, unpublished data), and the relative contri- 
bution of group-specific and type-spedfic anti-envelope CTL 
remains to be determined. 
CTL responses  directed at this conserved region of gp41 
are likely to exist in a significant percentage of HIV-1 seroposi- 
rive subjects. The HLA-B8 and B14 molecules are expressed 
on approximately 16% and 7% of the North American Cau- 
casian population and 6% and 8% of North American black 
population, respectively (19). HLA-B14-restricted CTL clones 
that recognize aa 584-592 have been obtained to date from 
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Figure 4.  Effect  of natural sequence  varia- 
tion on recognition  of  gp41-specific  CTL. Au- 
tologous B-I.CL were sensitized  with the in- 
dicated  concentration  of  peptide  and incubated 
with  either the B14-restricted CTL  clone 
115H10 (A) or the BS-restricted CTL line 
35/env128 (B) at E/T ratios of 3:1 and 5:1, 
respectively.  Pc'pride-specific  lysis  was calculated 
for the CTL line  35/env/128  by subtracting  the 
lysis of unsensitized  B-LCL from the lysis of 
peptide-sensitized  targets, which ranged  from 
8% to 15%. 
two other HIV-1 seropositive subjects, suggesting that rec- 
ognition of this epitope is common in HLA-B14-positive  sub- 
jects (R. P. Johnson, C. Jassoy,  and B. D. Walker, unpub- 
lished data). In addition, a peptide including both HLA-BS- 
and B14-restricted gp41 epitopes corresponding to aa 580-600 
of the HIV-1 envelope has been shown to bind to isolated 
HLA-A2 molecules in a solid phase assay, suggesting that 
the A2 allele may be able to present peptides from this re- 
gion (27).  Although the structural basis for overlapping T 
cell epitopes is not known, several examples have been reported 
recently, including MHC  class  I-restricted CTL  epitopes 
reported in the HIV-1 nef (28,  29) and gag (9, 30) proteins, 
and MHC class II-restricted T cell epitopes in other systems 
(31-33). 
It is important to note that our study differs from other 
recent reports on envelope-specific CTL (25, 34) in that CTL 
epitopes were identified in an inclusive fashion, rather than 
on the basis of screening against a subset of synthetic enve- 
lope peptides. In addition, effector cells used for the initial 
definition of the epitopes described here were not stimulated 
in vitro with viral antigen. Identification of T  cell epitopes 
using synthetic peptides chosen on the basis of amphipathicity 
(25)  or sequence conservation (34)  may underestimate the 
complete  repertoire  of the  anti-envelope  CTL  response. 
Moreover, characterization of CTL epitopes using effector 
cells produced by in vitro stimulation with irradiated HIV-1- 
infected lymphoblasts (34), a process that is able to induce 
CTL responses in HIV-1 seronegative subjects (2, 34,  35), 
raises the possibility that epitopes identified in this fashion 
may not accurately reflect epitopes recognized in vivo by HIV-1 
seropositive subjects. 
The region in gp41 containing the epitopes identified here 
appears to be important not only for HLA class I-restricted 
cytotoxic responses,  but also for a number of additional im- 
mune  functions.  The  HLA-B8  (aa  586-593)  and  B14 
(584-592)-restricted CTL epitopes partially overlap with an 
epitope  (aa  579-590)  recognized by  CD4 +  lymphocytes 
generated in seronegative subjects after immunization with 
a rgp160 vaccine (36).  A peptide from gp41 containing the 
class I HLA-B8 and B14 CTL epitopes and the class II CD4 
epitope has also been reported to induce proliferative responses 
in 24%  of seropositive subjects (37).  Association between 
class I and class II epitopes has also been noted for other HIV-1 
epitopes (25).  Interestingly, this region is also immediately 
adjacent to the immunodominant B cell epitope in gp41,  aa 
593-604 (38).  However, this region of gp41 also includes a 
peptide that has been proposed to have potential immunosup- 
pressive effects (39), and further studies are necessary to recon- 
cile these observations. 
An increasing body of evidence suggests that sequence vari- 
ation within critical epitopes of HIV-1 may lead to virus vari- 
ants that escape recognition by the host immune response 
(40, 41). HIV-1 genomes exhibit considerable sequence vari- 
ation, even within relatively conserved proteins such as gag 
(42) and tat (43).  However, only limited information exists 
regarding the impact of sequence variation on recognition 
by human HIV-l-specific CTL. Previous studies in a routine 
model have indicated that even a single aa change in the HIV-1 
envelope may abrogate recognition by virus-specific CTL (44). 
For the two gp41 epitopes described in this report, a conser- 
vative aa substitution resulted in either no effect on recogni- 
tion or a modest reduction of target lysis,  while a single 
nonconservative substitution resulted in a complete loss of 
recognition. For other HIV-1 epitopes, conservative aa sub- 
stitutions have also been observed to abolish lysis of target 
cells (36, R. P. Johnson and B. D. Walker, unpublished ob- 
967  Johnson  et al. Table  5.  Comparison  of Peptides Containing CTL Epitopes Presented by the HLA-B8 Molecules 
Antigen (aa coordinates)  Sequence*  Reference 
HIV-1 gl~l (586-593)  Y  L  K  D  Q  Q  r  L 
HIV-1p17(21-35)  L  R  P  G  G  K  KKYKL  KH  I  V 
HIV-lp17(21-35)  L  R  P  G  GKKKYK  L  KH  I  V 
HIV-1 p17  (21-35)  L  R  P  G  GKK  K  Y  KLK  H  I  V 
HIV-1p24(253-267)  N  P  P  I  P  V  G  EIYKRW  I  I 
HIV-1p24(253-267)  N  P  P  I  P  V  G  E  I  YKRWI  I(L) 
HIV-1p24(323-337)  VQN  A  N  P  D  C  KT  I  L  KA  L 
HIV-lp24(323-337)  V  QNANP  DC  K  T  I  L  K  A  L 
HIV-1RT(160-184)  I  E  TV  P  VKL  K  P  GMDG  PKVKQWP  LT  E  E 
HIV-1 KT(160-184)  I  E  T  V  P  VK  L  K  P  GMD  G  P  K  V  K  QwP  L  T  E  E 
EBVEBNA(334-353)  AWN  A  G  F  L  RG  RAYG  I  D  L  L  R  T  E 
EBVEBNA(334-353)  AWN  A  G  F  L  RGRAYG  I  D  L  L  R  T  E 
This report 
30 
9,  53 
30 
54 
* Eight- or nine-aa regions aligned with the HLA-B8-restricted  gp41 CTL epitope YLKDQQLL are shown in boldface and homologous aa are under- 
lined.  Alternative alignments  are shown for each peptide.  For one alignment of the p24  gag epitope 253-267,  an additional  aa corresponding  to 
the natural  sequence but not included in the sensitizing peptide is shown in parentheses.  All HIV-1 peptides are numbered  according to the HXB2R 
sequence ~16). 
servations). These results underscore the potential impact of 
sequence variation in HIV-1 to produce virus variants  that 
can escape immune recognition. 
In addition to allowing a precise assessment of the effects 
of sequence variation on recognition by CTL, the determi- 
nation of minimum CTL epitopes may also facilitate  the 
identification of alhle-specific motifs. The minimum epitopes 
identified here of eight and nine aa for the HLA-B8- and B14- 
restricted gp41 epitopes are consistent with the recent char- 
acterization of naturally processed peptides of eight or nine 
aa in both mouse and humans (45-50) and the crystalline 
structure of the peptide binding pocket of the HLA-B27 mol- 
ecule (51). The minimum epitopes defined in this study using 
serial truncations of synthetic peptides may well correspond 
to the naturally processed peptide, consistent with the ability 
of the octamer HLA-B8-restricted gp41 epitope to sensitize 
target cells at picomolar concentrations.  Allele-specific motifs 
have been proposed for several mouse MHC types and the 
HLA-A2 and B27 alldes (47--49, 52). Comparison of the HLA- 
B8-restricted gp41 epitope 586-593 with peptides containing 
other HLA-B8-restricted CTL epitopes (8, 9, 30, 53, 54) re- 
veals several potential alignments with shared characteristics 
at selected positions within an eight- to nine-aa region, in- 
cluding a hydrophobic residue (Ala, Leu, Iso, and Val) at po- 
sition two, a positively charged aa at position 3, and aa with 
nonpolar or small polar side chains at the two COOH-terminal 
residues (Table 5). Definitive assignment of an HLA-B8-specific 
motif will require the determination of minimum effective 
epitopes for other HLA-BS-restricted epitopes and the use 
of competition experiments with variant peptides to define 
aa  that interact with either  the TCR or  HLA  molecule 
(55-58). Additional HLA-B14-restricted  CTL epitopes need 
to be identified in order to propose a motif for this allele. 
Precise definition of epitopes recognized by CTL clones may 
improve our ability to predict immunogenic sequences based 
on aUde-specific  motifs. The significance of such allele-specific 
motifs is further emphasized by the fact that an algorithm 
that was developed to identify T cell epitopes based on am- 
phipathicity (59, 60) fails to identify epitopes described by 
other investigators  (61) and those in this report. 
Since the majority of HIV-1 vaccine candidates currently 
in clinical trials include the envelope protein as an immunogen 
(62, 63), further definition of the human CTL response to 
gp160 is likely to facilitate evaluation  of immune responses 
in vaccine recipients.  In the studies reported here, we have 
devised a technique whereby CTL can be expanded in vitro 
using stimulation with uninfected, irradiated,  autologous 
CD4 + lymphocytes incubated with  synthetic peptides as 
antigen-presenting calls. These data therefore indicate that 
CTL from HIV-l-infected persons can be expanded in vitro 
in an epitope-specific manner. This protocol has been suc- 
cessful in expanding CTL specific for other HIV-1 epitopes 
as well (data not shown), and may prove useful as a means 
of detecting low level or memory responses to HIV-1 pro- 
teins in HIV-1 vaccine recipients. 
In summary, these studies provide evidence that the highly 
conserved gp41 transmembrane protein serves as an impor- 
tant target for class I-restricted CTL. The identification of 
two overlapping CTL epitopes in gp41, which are restricted 
by different HLA molectfles, may be useful not only in subunit 
968  Overlapping Cytotoxic T  Lymphocyte Epitopes  in the HIV Envelope vaccine design, but should also be hdpful in defining CTL 
responses in HIV-1 vaccine recipients. The existence of CTL 
epitopes in the relatively conserved portions of the envelope 
glycoprotein suggests that vaccines capable of inducing CTL 
responses may be able to induce cross-reactive immunity. How- 
ever, in light of the ability of single aa changes, even conser- 
vative substitutions,  to abolish recognition by CTL, poten- 
tial  HIV-1  vaccines  should be designed  to  induce  cellular 
immune  responses  against  multiple  conserved  regions  of 
HIV-1. 
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